TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04060862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
Study: NCT00560469

Intervention type: OTHER
Intervention: Administration of 70% deuterated water
Description: Subjects will drink 70% deuterated water daily for 8 weeks.

Intervention type: OTHER
Intervention: Administration of 70% deuterated water
Description: Subjects will drink 70% deuterated water daily for 8 weeks.
Study: NCT02646254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood cardioplegia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: del nido cardioplegia
Study: NCT01420653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxigesic 325
Description: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
Study: NCT00450372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADI-PEG-20
Description: There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacology Studies
Description: tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
Study: NCT00256308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
Study: NCT01420653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, three tablets four times a day, with food for 48 hours
Study: NCT02498080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB PTA
Description: paclitaxel drug eluting balloon PTA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA
Description: Standard PTA
Study: NCT02087319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hair loss, baldness (patient's own platelet-rich plasma)
Description: hair loss, baldness
Study: NCT02364193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cardiac MRI for LVEF and segmentation.~* Phase-contrast MRI for CO in aorta and each pulmonary vein.~* DCE-MRI for bolus kinetic parameter analysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gd-CA
Description: Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
Study: NCT02963831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
Study: NCT02364193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS ImpediMed™ SFB7
Description: BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autotransfusion Lympamat Digital Gradient system
Description: Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
Study: NCT02493309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light activity breaks
Description: Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
Study: NCT00748826

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2
Study: NCT02963831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
Study: NCT01461356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee replacement
Description: A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard approach total knee replacement
Description: A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
Study: NCT02963831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
Study: NCT01663610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VardagsSMART
Description: VardagsSMART Internet-based course with therapist support during 6 weeks
Study: NCT01189955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HS total thyroidectomy
Description: In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional total thyroidectomy
Description: A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
Study: NCT00940017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin and voriconazole
Description: Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
Study: NCT04296162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine chemotherapy (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine chemotherapy (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab target therapy
Study: NCT02074566

Intervention type: OTHER
Group type: OTHER
Intervention: Cryoballoon ablation
Description: PVI using cryoballoon

Intervention type: OTHER
Group type: OTHER
Intervention: Cryoballoon ablation
Description: PVI using cryoballoon

Intervention type: OTHER
Group type: OTHER
Intervention: Cryoballoon ablation
Description: PVI using cryoballoon
Study: NCT00082485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00189020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7
Description: PCV7 at age 2 and 4 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7
Description: PCV7 at age 2, 4 and 11 months
Study: NCT03742843

Intervention type: COMBINATION_PRODUCT
Intervention: A multi-omics analysis
Description: A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium

Intervention type: COMBINATION_PRODUCT
Intervention: A multi-omics analysis
Description: A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
Study: NCT02214186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Fluid Therapy
Description: The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
Study: NCT03742843

Intervention type: COMBINATION_PRODUCT
Intervention: A multi-omics analysis
Description: A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
Study: NCT04107519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Directed Resilience Training
Description: This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
Study: NCT03225352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen (Dolormin Extra)
Description: Single intake of 1 tablet, 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen (Dolormin Extra)
Description: Single intake of 1 tablet, 400mg
Study: NCT04066257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 250 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 250 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline hydrochloride 250 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline hydrochloride 250 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Tripotassium bismuth dicitrate 300 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Tripotassium bismuth dicitrate 300 mg tablet
Study: NCT03826394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
Study: NCT04338334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual drainage & arm therapeutic exercise
Description: See arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cohesive bandaging & arm therapeutic exercise
Description: See arm/group descriptions.
Study: NCT02833636

Intervention type: PROCEDURE
Intervention: ACEF score

Intervention type: PROCEDURE
Intervention: ACEF score
Study: NCT02796742

Intervention type: OTHER
Intervention: Collecting samples from all patients presenting with SSTIs requiring drainage
Description: The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.

Intervention type: OTHER
Intervention: Collecting samples from all patients presenting with SSTIs requiring drainage
Description: The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
Study: NCT02206009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen Membrane
Description: First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
Study: NCT03516487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
Study: NCT03397160

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Support Intervention (DSI)
Description: A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps).
Study: NCT02023944

Intervention type: OTHER
Group type: OTHER
Intervention: Memory and Aging Course
Description: This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
Study: NCT00598702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
Study: NCT04416308

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NG test
Description: rapid diagnosis Covid 19

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NG test
Description: rapid diagnosis Covid 19

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NG test
Description: rapid diagnosis Covid 19

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NG test
Description: rapid diagnosis Covid 19

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test
Description: sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test
Description: sample

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-questionnary
Description: behavioral survey

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-questionnary
Description: behavioral survey

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-questionnary
Description: behavioral survey

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-questionnary
Description: behavioral survey
Study: NCT01742936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoaguChek
Description: Hand held coagulation monitor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoaguChek
Description: Hand held coagulation monitor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Laboratory
Description: Coagulation testing done by hospital laboratory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Laboratory
Description: Coagulation testing done by hospital laboratory.
Study: NCT03516487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.